

Frontiers in Clinical Drug Research

(CNS and Neurological Disorders)



Editor:
Zareen Amtul

Bentham Books

**Frontiers in Clinical Drug
Research - CNS and
Neurological Disorders**

(Volume 11)

Edited by

Zareen Amtul

*The University of Windsor
Department of Chemistry and Biochemistry
Windsor, ON
Canada*

Hi qpvgt ulp'EnplecnF t wi 'Tgugct ej ' /'EP U'cpf 'P gwt qmi lecnF luqt f gt u

Volume # 11

Editor: Zareen Amtul

ISSN (Online): 2214-7527

ISSN (Print): 2451-8883

ISBN (Online): 978-981-5123-31-9

ISBN (Print): 978-981-5123-32-6

ISBN (Paperback): 978-981-5123-33-3

©2023, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2023.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 MULTI-FUNCTIONAL LIGANDS AND MOLECULAR HYBRIDIZATION: CONCEPTUAL ASPECTS AND APPLICATION IN THE INNOVATIVE DESIGN OF DRUG CANDIDATE PROTOTYPES FOR NEURODEGENERATIVE DISEASES	1
<i>Flávia Pereira Dias Viegas, Vanessa Silva Gontijo, Matheus de Freitas Silva, Cindy Juliet Cristancho Ortiz, Graziella dos Reis Rosa Franco, Januário Tomás Ernesto, Caio Miranda Damásio, Gabriel Pinto da Silva Fonseca, Isabela Marie Fernandes Silva, Larissa Emika Massuda, Maria Fernanda da Silva, Thâmara Gaspar Campos, Priscila da Mota Braga and Cláudio Viegas, Jr.</i>	
INTRODUCTION	2
THE MTDLS PARADIGM AND MOLECULAR HYBRIDIZATION (MH) AS A TOOL IN DRUG DESIGN	3
GENERAL ASPECTS OF MULTIFACTORIAL PATHOGENESIS IN NDS	5
Alzheimer's Disease (AD)	5
Parkinson's Disease (PD)	7
Amyotrophic Lateral Sclerosis (ALS)	10
Huntington's Disease (HD)	11
MOLECULAR HYBRIDS AND CHEMICAL DIVERSITY OF MULTIFUNCTIONAL LIGANDS RATIONALLY DESIGNED AS NEW DRUG CANDIDATES FOR NDS	12
CONCLUDING REMARKS	133
CONSENT FOR PUBLICATION	134
CONFLICT OF INTEREST	134
ACKNOWLEDGEMENTS	134
REFERENCES	134
CHAPTER 2 DRUGS FOR RELAPSE PREVENTION IN ADDICTION: REVIEW OF PSYCHOLOGICAL AND NEUROLOGICAL FACTORS, GENETICS AND NEUROBIOLOGICAL MECHANISMS	158
<i>Cheng Hua</i>	
INTRODUCTION	158
PSYCHOLOGICAL AND NEUROLOGICAL RISK FACTORS OF BEHAVIORAL ADDICTION	159
Behavioral Addiction	159
<i>Behavioral Addiction and Substance Addiction</i>	<i>159</i>
<i>Behavioral Addiction and Addictive Behavior</i>	<i>160</i>
<i>Neurobiological Theories of Behavioral Addiction</i>	<i>160</i>
<i>Theoretical Models of Addictive Disorders</i>	<i>161</i>
<i>The General Theory of Addictions by Jacobs</i>	<i>161</i>
<i>The Excessive Appetites Model of Addictions by Orford</i>	<i>162</i>
<i>The Syndrome Model of Addiction</i>	<i>162</i>
<i>The Components Model of Addiction by Griffiths</i>	<i>162</i>
Interaction of Person-Affect-Cognition-Execution (I-PACE) Model	162
<i>The P-component of the I-PACE Model</i>	<i>163</i>
<i>The A-, C-, and E-components of the I-PACE Model</i>	<i>164</i>
GENETICS AND NEUROBIOLOGICAL PATHWAYS BEHIND ADDICTION	165
Brain Reward System (BRS)	165
<i>Biological Circuits Related to Reward System</i>	<i>166</i>
<i>Neurobiology Pathways Behind Stages Cycle to Addiction</i>	<i>171</i>

<i>Neurobiology of Relapse</i>	174
Genetics and Epigenetic Mechanism	176
.....	176
<i>Epigenetic Regulation</i>	178
<i>Synaptic Plasticity Underlying Drug-Induced Addiction-like Behavior</i>	183
PHARMACOTHERAPY FOR RELAPSE PREVENTION SUD	184
Drugs for Relapse Prevention in Addiction	186
<i>Medications to Treat Alcohol Use Disorder (AUD)</i>	186
<i>Smoking Cessation Therapy</i>	192
<i>Genomic Medicine for Tobacco Use Disorder (TUD)</i>	194
<i>Medications for Opioids Use Disorder (OUD)</i>	194
<i>Drug Discovery and Development for Addiction</i>	195
<i>Quantitative Systems Pharmacology (QSP)</i>	196
Lead Immunotherapy for SUD	199
<i>Drug Conjugate Vaccine</i>	199
<i>Monoclonal Antibodies</i>	205
CONCLUSION	206
CONSENT FOR PUBLICATION	207
CONFLICT OF INTEREST	207
ACKNOWLEDGEMENTS	207
REFERENCES	207
CHAPTER 3 NEUROPROTECTIVE ACTIVITIES OF CINNAMIC ACIDS AND THEIR DERIVATIVES	238
<i>Pronit Biswas, Rajesh Singh Yadav and Juli Jain</i>	
INTRODUCTION	239
CELL DEATH IN NEURODEGENERATION	242
CINNAMIC ACID	243
Naturally Occurring Cinnamic Acid Derivatives	243
Synthetic Derivatives of Cinnamic Acid	246
PHARMACOLOGICAL ACTIVITIES OF CINNAMIC ACIDS AND THEIR DERIVATIVES IN NEURODEGENERATIVE DISEASES	246
Parkinson's Disease	246
Alzheimer's Disease	248
Huntington's Disease	250
Prion Disease	251
Ischemic Brain Injury	252
FUTURE CHALLENGES	253
CONCLUSION	253
CONSENT FOR PUBLICATION	254
CONFLICT OF INTEREST	254
ACKNOWLEDGEMENTS	254
REFERENCES	254
CHAPTER 4 PHYTOSOME FOR TARGETED DELIVERY OF NATURAL COMPOUNDS: IMPROVING EFFICACY, BIOAVAILABILITY, AND DELIVERY ACROSS BBB FOR THE TREATMENT OF ALZHEIMER'S DISEASE	262
<i>Prashant Tiwari, Geetha KM, Shweta Shrivastava, Yogita Kumari, Rajni Kant Panik, Pankaj Kumar Singh, Dileep Kumar and Pratap Kumar Sahu</i>	
INTRODUCTION	263
Conventional Therapy Against AD	264
Blood Brain Barrier and AD	264

Neuroprotective Potential of Herbal Drugs	266
Herbal Drugs Used in AD	267
Nanotherapeutics to Improve BBB Permeability	268
Polymeric Nanoparticles	269
Nanogels	269
Solid Lipid Nanoparticles	270
Nano Lipid Carrier	271
Target Specific Nanoparticles	271
Phytosome	272
Therapeutic Applications of Phytosome	273
CONCLUDING REMARKS	275
CONSENT FOR PUBLICATION	275
CONFLICT OF INTEREST	275
ACKNOWLEDGEMENTS	276
REFERENCES	276
CHAPTER 5 ALZHEIMER'S DISEASE AND PHYSICAL ACTIVITY, WILL THE SYMPTOMS IMPROVE?	283
<i>Maryam Hamzeloo-Moghadam</i>	
INTRODUCTION	283
Risk Factors	284
Pathology	284
Pharmacologic Treatment of Alzheimer's Disease	284
Cholinesterase Inhibitors	284
N-methyl-D-aspartate (NMDA) Receptor Antagonists	285
Should Non-Pharmacologic Treatments Be Involved?	285
Physical Function and Activities of Daily Living (ADL)	287
Fall Risk and Balance	293
Neuropsychiatric Symptoms	295
Cognitive Function	298
Communication	299
Sleep Disturbance	300
Cardiorespiratory Improvement	300
Combination Therapy	300
Influence of Physical Activity on Risk for AD	301
CONCLUSION	307
CONSENT FOR PUBLICATION	308
CONFLICT OF INTEREST	308
ACKNOWLEDGEMENTS	308
REFERENCES	308
SUBJECT INDEX	536

PREFACE

Studying brain physiology and development is a leading neuroscience strategy not only to illuminate the general understanding of brain structure and function but also to make progress against neurodegenerative disorders that are devastating the healthy aging.

The volume 11 of our book series *Frontiers in Clinical Drug Research - CNS and Neurological Disorders* introduces the subject of neurodegeneration by outlining the pathophysiology genetics, and environmental factors. This book besides providing a clear overview of the neurodegeneration and addiction process also introduces the readers to a new synthesis of ideas. To contextualize the research for the general readers, it also provides a brief introduction to the pharmacological and non-pharmacological approaches to treat the commonest neurodegenerative and addictive disorders. This book takes interested beginners on a journey from a cold start to a grasp of neuroscience's best line of research. The current volume integrates the work of neurobiologists into a coherent account of the nature of neurodegenerative and addictive disorders and their treatment.

For instance, **Chapter 1** highlights the multi-target directed ligands candidate prototypes inspired mostly by natural products to treat some of the most studied diseases, namely, Parkinson's Disease, Alzheimer's Disease, and Huntington's Disease, as well as amyotrophic lateral sclerosis. **Chapter 2** discusses the role of psychological and neurological factors as well as genetics and neurobiological mechanisms to review the drugs used for relapse prevention to treat addiction to nicotine, alcohol, or illicit drugs. **Chapter 3** summarizes the neuroprotective properties of cinnamic acids and their derivatives in light of their mechanistic aspects to treat various neurodegenerative disorders. **Chapter 4** reviews the role of phytosome in the targeted delivery of natural compounds across the blood brain-barrier to improve the efficacy, and bioavailability of Alzheimer's drugs. **Chapter 5** glances at clinical trials investigating non-pharmacologic approaches, such as physical activity to improve the symptoms of Alzheimer's Disease.

Briefly, this volume is the definitive guide to common neurodegenerative diseases that affect humans. The book covers the mechanisms of some of the most well-known neurodegenerative and addictive diseases, their biomarkers, neuropharmacology, and emerging treatment strategies.

We are grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications), and Ms. Asma Ahmed (Senior Manager Publications) at Bentham Science Publishers.

Zareen Amtul
The University of Windsor
Department of Chemistry and Biochemistry
Windsor, ON
Canada

List of Contributors

Cindy Juliet Freitas Silva	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Caio Miranda Damásio	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Claudio Viegas	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil Programa de Pós-Graduação em Ciências Farmacêuticas, Federal University of Alfenas, 37133-840, Brazil
Cindy Juliet Cristancho Ortiz	Programa de Pós-Graduação em Química, Federal University of Alfenas, 37133-840, Brazil
Cheng Hua	Department of Surgery, Dongguan First Hospital Affiliated to Guangdong Medical University, China
Flávia Pereira Dias Viegas	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Graziella dos Reis Rosa Franco	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil Programa de Pós-Graduação em Química, Federal University of Alfenas, 37133-840, Brazil
Gabriel Pinto da Silva Fonseca	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Geetha KM	College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore, Karnataka, India
Isabela Marie Fernandes Silva	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Januário Tomás Ernesto	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Juli Jain	Neuroscience Research Lab, Department of Zoology, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar – 470003 (MP), India
Larissa Emika Massuda	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Matheus de Freitas Silva	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil Programa de Pós-Graduação em Química, Federal University of Alfenas, 37133-840, Brazil
Maria Fernanda da Silva	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Maryam Hamzeloo-Moghadam	Traditional Medicine and Materia Medica Research Center and Department of Traditional Pharmacy, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Priscila da Mota Braga	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Pronit Biswas	Department of Criminology and Forensic Science, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar – 470003 (MP), India
Prashant Tiwari	College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore, Karnataka, India
Pankaj Kumar Singh	National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India
Pratap Kumar Sahu	School of Pharmaceutical Sciences , Siksha O Anusandhan (Deemed to be University), Bhubaneswar, India
Rajesh Singh Yadav	Department of Criminology and Forensic Science, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar – 470003 (MP), India
Rajni Kant Panik	Department of Pharmaceutics, Royal College of Pharmacy, Raipur, Chhattisgarh, India
Rajni Kant Panik	Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharti Vidyapeeth University, Pune, India
Shweta Shrivastava	School of Pharmacy, Arka Jain University, Jamshedpur, Jharkhand, India
Thâmara Gaspar Campos	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil
Vanessa Silva Gontijo	PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil Programa de Pós-Graduação em Ciências Farmacêuticas, Federal University of Alfenas, 37133-840, Brazil
Yogita Kumari	School of Pharmacy, Arka Jain University, Jamshedpur, Jharkhand, India

CHAPTER 1**Multi-functional Ligands and Molecular Hybridization: Conceptual Aspects and Application in the Innovative Design of Drug Candidate Prototypes for Neurodegenerative Diseases**

Flávia Pereira Dias Viegas^{1,3}, Vanessa Silva Gontijo^{1,2}, Matheus de Freitas Silva^{1,3}, Cindy Juliet Cristancho Ortiz^{1,3}, Graziella dos Reis Rosa Franco^{1,3}, Januário Tomás Ernesto^{1,2}, Caio Miranda Damásio¹, Gabriel Pinto da Silva Fonseca¹, Isabela Marie Fernandes Silva¹, Larissa Emika Massuda¹, Maria Fernanda da Silva¹, Thâmara Gaspar Campos¹, Priscila da Mota Braga¹ and Claudio Viegas, Jr.^{1,2,3,*}

¹ *PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil*

² *Programa de Pós-Graduação em Ciências Farmacêuticas, Federal University of Alfenas, 37133-840, Brazil*

³ *Programa de Pós-Graduação em Química, Federal University of Alfenas, 37133-840, Brazil*

Abstract: The rapid increase in the incidence of dementia has enormous socio-economic impacts and costs for governmental health systems all over the world. Despite this, finding an effective treatment for the different types of neurodegenerative diseases (NDs) so far represents a challenge for science. The biggest obstacles related to NDs are their multifactorial complexity and the lack of knowledge of the different pathophysiological pathways involved in the development of each disorder. The latest advances in science, especially those related to the systems biology concepts, have given new insights for a better comprehension of such multifactorial networks related to the onset and progression of NDs, and how Medicinal Chemists could act in the search for novel disease-modifying drug candidates capable of addressing the multiple pathological factors involved in neurodegeneration. The multi-target directed ligands (MTDLs) concept has captivated and opened new windows for the creativity and rationality of researchers worldwide in seeking innovative drug candidates capable of modulating different molecular targets by a single multifunctional molecule. In fact, in

* **Corresponding author Claudio Viegas Jr:** PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840, Brazil ; Programa de Pós-Graduação em Ciências Farmacêuticas, Federal University of Alfenas, 37133-840, Brazil
E-mail: cvjviegas@gmail.com

Zareen Amtul (Ed.)

All rights reserved-© 2023 Bentham Science Publishers

the last two decades, thousands of research groups have dedicated their efforts to the use of molecular hybridization as the main tool for the rational design of novel molecular scaffolds capable of expressing multi-target biological activity. In this way, this chapter addresses the most recent pathophysiological hallmarks of the most high-impact NDs, represented by Alzheimer's, Parkinson's, Huntington's diseases, and amyotrophic lateral sclerosis, as well as the state-of-art in the design of new MTDLs, inspired mostly by natural products with improved druggability properties.

Keywords: Molecular Hybridization, MTDLs, Multi-target Directed Ligands, Multifunctional Drugs, Neurodegenerative Diseases, Rational Drug Design.

INTRODUCTION

Neurodegenerative diseases (NDs) are recognized as a group of incurable, severe, progressive and disabling chronic neurological pathological conditions, with great social and economic impacts worldwide, representing one of the biggest current challenges for all sciences focused on human health [1 - 6]. Currently, due to their high incidence and epidemiological impact, NDs have Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) as their main representants, as attested in the scientific literature for the enormous efforts in drug discovery, pharmacological and biological projects addressed for the discovery of novel drug candidate, innovative therapeutics and a continuous search for a better comprehension of their pathophysiological features. Today, it is estimated that about 50 million people have some type of dementia worldwide and that this number is increasing by 10 million new cases every year [7], and medical treatments are onerous and are predicted to amount to 2 trillion US dollars in 2030 [8].

These four main types of NDs have been currently recognized as chronic inflammatory pathologies, also characterized by multiple interconnected physiological, biochemical, and cellular changes, along with chemical mediators operating concurrently and caused by the same or different pathways [5, 6, 9 - 12]. During the last decade, we have observed considerable efforts and investments from Governmental and non-Governmental sources, resulting in major advances in different fields of biological and chemical sciences and the consequent establishment of new insights into the knowledge of how complex and multifaceted the pathophysiological hallmarks of NDs are. Despite the efforts of research centers to discover new drugs for NDs, many have failed in clinical trials [8].

Aging is currently well accepted as one of the main risk factors related to the NDs onset, but why are some people more susceptible than others to be affected by ND? The answer to this question seems to be related to neuronal cells'

vulnerability, which states that different neuronal cells of the central and peripheral nervous systems are exposed and affected differently by environmental and age-related changes, resulting in a time-dependent decline in cognition, memory, sensory, and motor coordination [5, 11, 13 - 16]. Meanwhile, which nervous region and type of neurons are most affected by aging during life is an individual factor. Despite aging, all these NDs are also related to genetic, epigenetic, and environmental factors. Rare cases of early onset of AD, PD, and ALS are determined by mutations in specific genes, leading to the occurrence of symptoms at 30-40 years old. In general, most cases of dementia are associated with alterations in neuronal physiology as an effect of protein misfolding, imbalance in oxidative processes, neuroinflammation, and mitochondrial dysfunction [6, 12, 13, 17 - 21]. Recent progress in neurobiology has decisively contributed to clarifying how specific neurons, in specific brain regions and under specific conditions, are more susceptible to molecular, morphological, and functional changes, leading to neurodegeneration and, in turn, how this selective neuronal vulnerability could be the basis of the changes observed in the behavior of neuronal cells, their susceptibility, and responsiveness to aging differently than other non-neuronal cells. Indeed, there is enough evidence that brain cells experience much more exacerbated effects due to oxidative stress (OS), energy supply perturbation, and deleterious effects of protein deposition. Moreover, as age advances, different populations of neurons in different brain regions seem more vulnerable to these biochemical changes, leading to individual responses to and determining which one will develop or not ND, consequently to genetic and environmental factors [5, 6, 11, 13, 16].

Considering the multifactorial related to NDs, their onset, progression, and severity, a better understanding of the relatively low efficacy of current disease-modifying treatments based on selectively targeted drugs is possible. In this context, and due to the high adaptive ability of our organism and the many concurrent biochemical pathways to be modulated for a single pathology, the most recent literature data point out that it is unavoidable to adopt a new concept for the rational design of drug candidates for the treatment of such multifactorial disorders [1, 4 - 6, 9, 22, 23]. Thus, the multi-target directed ligands (MTDLs) have emerged as a polypharmacology-based strategy for drug design, and it has called special attention from the scientific community [8].

THE MTDLs PARADIGM AND MOLECULAR HYBRIDIZATION (MH) AS A TOOL IN DRUG DESIGN

Considering the multitude of interconnected cellular and biochemical factors associated with the onset, development, and pathophysiological complexity of NDs, and the lack of efficacy of the current chemotherapeutical practices, it

Drugs For Relapse Prevention in Addiction: Review of Psychological and Neurological Factors, Genetics and Neurobiological Mechanisms

Cheng Hua^{1,*}

¹ Department of Surgery, Dongguan First Hospital Affiliated to Guangdong Medical University, China

Abstract: Behavioral and substance addictions share more similarities than differences in etiological, phenomenological, and clinical presentations. Interactions between the variables of predisposing (*i.e.*, neurobiological and psychological constitutions) and moderating (*i.e.*, coping style and cognitive and attentional biases), as well as variables of mediating (*i.e.*, affective and cognitive reactions to situational triggers) in combination with reduced inhibitory control may accelerate or reduce the developing of specific versions of model for addictive behaviors. Around 50% individuals' variability in becoming addicted to substance (nicotine, alcohol, or illicit drugs) is attributable to genetic factors. Genetic variations to addiction susceptibility and environmental factors such as stress or social defeat also alter brain-reward mechanisms impart vulnerability to addiction. The emergence and maintenance of addiction might be the consequences of chronic exposure to drugs remodeling the chromatin structure including FosB, Cdk5, G9a, and BDNF around genes. Only few drugs for substance use disorders (SUDs) are approved by the FDA, But QSP approaches provide valuable strategies for designing novel prevention or treatment towards drug addiction. Conjugate vaccines and monoclonal antibodies treatments generating high-affinity anti-drug IgG antibodies neutralizing drug doses in the serum might lead the immunotherapy for SUDs in the future.

Keywords: Addiction, Alcohol Use Disorder (AUD), Brain reward system (BRS), Conjugate vaccine, Genome-wide association study (GWAS), Monoclonal antibodies, Nicotine, Opioids Use Disorder (OUD), Quantitative systems pharmacology (QSP).

INTRODUCTION

The term addiction can be traced to Roman law according to the Oxford English

* Corresponding author Cheng Hua: Department of Surgery, Dongguan First Hospital Affiliated to Guangdong Medical University, China; Tel: +8613828217170; E-mail: hua.cheng@icpbr.ac.cn

Dictionary in page 24-25. From behavioral neuroscience, epidemiology, genetics, molecular biology, pharmacology, psychology, psychiatry to sociology, the study of addictive behavior is interdisciplinary [1]. “Addiction” reflecting individuals in pursuing reward and/or relief by substance use and behaviors, it is also defined by the American society of addiction medicine as a chronic disease of brain reward, motivation, memory and related circuitry. Addiction is included as a category by Diagnostic and Statistical Manual of Mental Disorders and contains both substances use disorders and non-substance use disorders [2]. Expert explained the Syndrome Model of Addiction in a revised view that an object of addiction can be a drug or drug-free activity. And the drug or activity must shift a person’s subjective experience in a desirable direction (feeling good or better) for addiction to develop.

The characteristics of addiction are behavioral control impairment, craving, to consistently abstain inability, and diminished recognition of one's behaviors and interpersonal relationships. Addiction ranges from substance use disorder to addictive behaviors. Addictions involve substance (alcohol, tobacco, opioids, prescription drugs, cocaine, cannabis, amphetamines, hallucinogens, inhalants, phencyclidine and other unspecified substances [3 - 11]) are psychological and those not involving a substance are behavioral (food eating, sex, pornography, using computers/ internet, playing video games, working, exercising, spiritual obsession, pain, cutting, shopping [12 - 24]).

Scientific advances in brain-imaging technologies and genetic researches suggest that specific substance or behavioral addiction is less important than previously believed. Instead, addiction acts functionally between a person and an object or activity. The object or activity with addiction becomes increasingly more important [25] and ultimately, addiction become complex struggle between acting on impulse and resisting that impulse [26].

PSYCHOLOGICAL AND NEUROLOGICAL RISK FACTORS OF BEHAVIORAL ADDICTION

Behavioral Addiction

Behavioral Addiction and Substance Addiction

A core defining concept of addiction is diminished control. Despite knowledge of adverse consequences, behaviors or ingesting psychoactive substance producing short-term reward engender persistent behavior, *i.e.*, diminished control over the behavior. The non-substance or “behavioral” addictions, with syndromes analogous to substance addiction in the conception, but with a behavioral focus other than psychoactive substance ingestion [27, 28]. In fact, addiction of

behavioral and substance share more similarities than differences in etiological, phenomenological, and clinical presentations [29].

Not all disorders characterized by impulsivity considered to be behavioral addictions. Behavioral disorders of pathological gambling or kleptomania, classified as impulse control disorders by Diagnostic and Statistical Manual, 4th Edition (DSM-IV-TR) have similarities to substance addictions. Other impulse control disorders like compulsive shopping, pathologic skin-picking, sex addiction, excessive tanning, computer/video game playing, and internet addiction, *et al.*, have been planned for inclusion in the DSM-V.

Behavioral Addiction and Addictive Behavior

Addiction producing pleasure and providing escaping from internal discomfort, is characterized by powerlessness to control behaviour and unmanageability of the behaviour continuation despite knowing significant negative consequences [30]. The object of behavioral addictions (BAs) can be any behavior that could produce pleasure and provide relief. Gambling disorder (GbD) and gaming disorder (GmD) are two currently recognized in international classifications of BAs. GbD was the first acknowledged BA in the “Substance-related and addictive disorders” section of the DSM-V in 2013. The second acknowledged BA defined in 2018 in the eleventh edition of the International Classification of Disease (ICD-11) was GmD in section of “addictive behavior” [31]. Sexual addiction (SA), eating addiction [32], excessive exercise [33], kleptomania [34], or shopping addiction are other pathological behaviors are often reported as BAs in the literature.

Neurobiological Theories of Behavioral Addiction

The four neurobiological theories of addiction help the construction and understanding of addiction theory.

Learning theory. Learning theory assumed that action-outcome learning and stimulus-response or ‘habit’ learning are two learning processes relevant to understanding addiction [35]. Theory hypothesis that stimulates-response learning occurs with instrumental action-outcome learning parallelly, but eventually dominates behavioral output with extended training.

Dysregulation theory. Addiction is the pathology outcomes of allostatic mechanism with the natural rewards circuits. Dysregulation theory believed addiction is brain reward systems dysregulation in the increasing spiraling progressively into a circle of compulsive use and loss of control. There are different reinforcement sources, neuro-adaptive mechanisms and neurochemical changes to the brain reward circuits system are involved in this dysregulation. The

Neuroprotective Activities of Cinnamic Acids and their Derivatives

Pronit Biswas^{1*}, Rajesh Singh Yadav¹ and Juli Jain²

¹ Department of Criminology and Forensic Science, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar – 470003 (MP), India

² Neuroscience Research Lab, Department of Zoology, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar – 470003 (MP), India

Abstract: Neurodegenerative disorders are considered major global health problems associated with nervous system dysfunction, progressive neuronal cell loss with aging, and several pathological and sporadic factors. Parkinson's disease, Alzheimer's disease, Prion disease, Huntington's disease, and multiple sclerosis are the main neurodegenerative diseases that raise significant concern among health scientists. The etiology of different neurodegenerative diseases is different, and they majorly affect the nervous system, including the brain, spinal cord, and peripheral nervous system. Neurodegenerative diseases are linked with motor dysfunction, anxiety, memory loss, depression, cognitive impairments, *etc.* These diseases can be hereditary or caused by toxicity, metabolic disorders, or pathological changes in the brain. Therefore, interest has been growing in the development of different neuroprotective agents of natural origin that could work effectively against these diseases. In that aspect, phytochemicals have shown high potential with minimal side effects in various *in vitro* and *in vivo* studies. Cinnamic acids with phenylpropenoic moiety are abundant in many natural resources. These are available in many forms, such as ferulic acid, caffeic acid, *etc.* They also have a variety of pharmacological properties, including anti-inflammatory, anti-oxidant, anti-amyloid, and neuroprotective properties. This chapter summarizes the role of naturally occurring cinnamic acids and their derivatives to develop the mechanistic aspects of neuroprotective therapeutics in neurodegenerative diseases. Future challenges are also discussed to provide beneficial information and therapeutic strategies.

Keywords: Alzheimer's disease, Cinnamic acid, Huntington disease, Neuroprotection, Parkinson's disease.

* Corresponding author Pronit Biswas: Department of Criminology and Forensic Science, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar – 470003 (MP), India; Tel:+91-9516232440; E-mail: pronitbond28@gmail.com

INTRODUCTION

Neurological diseases influence almost 50 million individuals around the world [1]. However, no medications for such diseases are pharmacologically effective for prescribing in these conditions [2, 3]. Aging prompts unfavorable changes in the brain with time, and it is a significantly dangerous factor for several neurological diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), similar to a stroke. Accordingly, the aging cycle should be studied in order to comprehend the molecular and cellular premise of neurological problems [4, 5]. By the end of 2050, the number of AD patients could reach around 150 million [6]. It has been observed that AD is prevalent in around 0.3% of the population in industrialized countries. This increases with age, rising from 1% of those over 60 to 4% of those over 80. Although the average age of onset is around 60 years, 10% of cases begin at a young age, between 20 and 50. PD is more common in men than in women, with publications citing ratios ranging from 1.1:1 to nearly 3:1 [7]. HD is found worldwide, with a prevalence of around ~12 per 0.1 million among individuals of European descent [8]. The motor symptoms (known as motor onset) can start from a young age in children, and around 45 years in adults, followed by inexorable progression [9].

Neurological diseases can be caused by mutant genetic genes and environmental factors (including sporadic aging and lifestyle). These diseases have standard features like excitotoxicity, reactive oxidative stress (ROS), mitochondrial dysfunctions, synaptic dysfunction, intracellular calcium dysregulation, misfolded protein aggregation, trophic factors, transcription and translation disruptions, axonal transport deficit, and finally, cell loss. Early cognitive and emotional manifestations seen in neurodegenerative disease patients are generally because of the debilitated synaptic and abnormal cellular functions. The disturbed cells that work along with the aging-actuated gathering of damaged DNA and oxidative stress pressure slowly overpower the self-protection framework, including quality control framework (for instance, ubiquitin and autophagy), and others, prompting a change in life, passing equilibrium, and coming full circle in customized cell death or programmed cell death [10]. Many have contended that deficits in brain bioenergetics and metabolism related to aging are fundamental to improving cognitive decline. Mitochondria are essential for energy, and their impairment has been implemented in the aging cycle and positively in neurological disorders [11]. However, little advancement has been made to prevent mitochondrial dysfunctions for improving cognitive brain health [12]. Accordingly, it is important to investigate the changes in mitochondria with aging and disease-associated injury or any other sporadic factors for therapeutic advancement in neurological disorders.

Natural products characterized as small molecular compounds are found naturally in plants, micro-organisms, and animals. These natural products have been utilized for different remedies in different diseases for thousands of years and are demonstrated to be a significant source of new drugs. As per the latest statistics of the US FDA-endorsed drugs, numerous professionally prescribed prescriptions to remedy different diseases are obtained from natural products [13]. Over the years, mitochondrial-targeted natural products have emerged in the discovery of neuroprotective therapeutics. These include possible therapeutics to improve mitochondrial dysfunction, modulate mitochondrial dynamics metabolism, maintain mitochondrial layer potentials, improve mitochondrial bioenergetics, calcium homeostasis, oxidative stress scavenging activities, and anti-inflammatory activities, as well as reduce apoptosis and resolve irregular characteristics in pathological conditions in neurological diseases like AD, PD, HD, multiple sclerosis, and Prion disease [14] (Fig. 1). It has been observed that cinnamic acid, ferulic, and their derivatives possess numerous biological activities against several neurological diseases Table 1 [14 - 20].




Fig. (1). Cinnamic acid and their derivatives in neuroprotection. α -syn- α -Synuclein, $A\beta$ - Amyloid β protein, AchE- Acetylcholinesterase, BuChE- Butyrylcholinesterase, TNF- α - Tumor necrosis factor- α , effects in neurodegeneration and effects in Cinnamic acid their derivative's neuroprotection.

Phytosome for Targeted Delivery of Natural Compounds: Improving Efficacy, Bioavailability, and Delivery across BBB for the Treatment of Alzheimer's Disease

Prashant Tiwari^{*1}, Geetha KM¹, Shweta Shrivastava², Yogita Kumari², Rajni Kant Panik³, Pankaj Kumar Singh⁴, Dileep Kumar⁵ and Pratap Kumar Sahu⁶

¹ College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore, Karnataka, India

² School of Pharmacy, Arka Jain University, Jamshedpur, Jharkhand, India

³ Department of Pharmaceutics, Royal College of Pharmacy, Raipur, Chhattisgarh, India

⁴ National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India

⁵ Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharti Vidyapeeth University, Pune, India

⁶ School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, India

Abstract: Alzheimer's disease (AD) is a progressive neurological disorder. Recent studies show that AD is the most common cause of dementia. There are several symptomatic treatments available to counterbalance the neurotransmitter disturbance. Currently, cholinesterase inhibitors are available for the treatment of mild to moderate AD. In addition to that, memantine (an N-methyl-D-aspartate receptor non-competitive antagonist) is also available for moderate to severe AD. Poor blood-brain barrier permeability is a limitation of existing drugs. These drugs may slow the disease progression, but there are chances of reoccurrence of the disease. Several medicinal plants such as *Jasminum sambac*, *Rosmarinus officinalis*, *Eucalyptus globulus*, *Nigella sativa*, and *Acorus gramineus* are reported to have neuroprotective effects. *Salvia officinalis* has cholinergic binding properties. Ginger root extract may prevent behavioral dysfunction in AD. Extensive research on these plants should be carried out. Drug delivery systems such as lipid nanoparticles, polymer nanoparticles, nanomicelles, nano-gels, liposomes, phytosomes, *etc.*, could significantly improve the pharmacokinetics, stability, efficacy and reduce the side effects. Phytosomes have the advantage over other drug delivery systems to selectively target the drugs into the brain. In contrast to traditional approaches, polar phytoconstituents loaded phytosomes

* Corresponding author Prashant Tiwari: Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore, Karnataka, India; E-mail: cologyprashant87@gmail.com/ prashanttiwari-sps@dsu.edu.in

are more bioavailable on the site of brain tissue, as they can easily go for systemic circulation crossing the Blood-Brain Barrier (BBB). Phytosomes have a low hazard profile as toxicological outcomes are negligible and assure duration of action at a low-risk profile due to upgraded absorption of the active constituents. In addition to this, the improved pharmacodynamic properties of phytosomes make them suitable for the treatment of neurological disorders.

Keywords: Brain cell, Cholinesterase inhibitors, Herbal extract, Liposome, Nano-gels, Phytosomes.

INTRODUCTION

Alzheimer's disease (AD) is a neurodegenerative disorder. It is associated with loss of memory and other cognitive abilities. It is the most common cause of dementia. It accounts for 60-80% of dementia cases. Age is also one of the major causes of AD. There is an increased incidence of AD in people above 65 years of age [1]. In the global scenario, people affected with dementia accounted for about 46.8 million people in 2018, and this figure went up to 50 million in 2020, and the expected prevalence is to be nearly 75 million by 2030. Pathological and biochemical factors also contribute to AD [2]. Cholinergic deficiency is associated with AD. There are very few drugs available for the treatment of AD, though the prevalence of AD is increasing day by day; on the contrary, the treatment modality is limited due to various factors, including the Blood-brain barrier (BBB) [3].

Nature is a good source of medicines. However, written records about medicinal plants date back at least 5,000 years to the Sumerians, who described well-established medicinal uses such plants as laurel, caraway, and thyme [4]. However, due to the high molecular weight of herbal medicines and poor solubility, herbal medicines have less brain permeability. In such a situation, a drug delivery system that can increase the solubility and brain availability of the drugs is desired [5]. Therefore, phytosome based drug delivery systems may be a promising tool for delivering the drugs to the central nervous system [6]. Phyto means part of plants and 'some' means lipid mixture. So, herbal drugs embedded in biodegradable lipids are called Phytosomes [7]. Phytosome can be used for improving blood-brain permeability in AD [8]. Considering the above facts, this article aims to summarize the previous findings and latest updates related to phytosomes technology and demonstrate their potential for the development of novel therapeutics in the treatment of AD.

Conventional Therapy Against AD

There are several symptomatic treatments available to counterbalance the neurotransmitter disturbance in AD. Currently, cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine are available for the treatment of mild to moderate AD. They may slow down the disease progression and curb the breakdown of a certain chemical (acetylcholine) in the brain cell. However, these drugs have common side effects like loss of appetite, weight loss, vomiting, nausea, fatigue, diarrhea, and insomnia [9 - 11].

In addition to that, memantine (an N-methyl-D-aspartate receptor non-competitive antagonist) is also available for moderate to severe AD. These treatment options are capable of blocking the disease progression because they may interfere with several pathogenic steps, including inflammation, oxidative damage, iron deregulation, cholesterol metabolism, deposition of extracellular amyloid β plaques, and intracellular neurofibrillary tangle formation [12]. In spite of that, poor blood-brain permeability of existing drug therapy is still a big question because they may delay the disease progression, but there is a chance of reoccurrence of the disease. Again, the limitations of Anti-AD drugs are due to their ineffective action as they reach their target cells in low concentration due to BBB [13]. So, there is a need to find new therapeutic drugs that can effectively counteract neurodegenerative diseases [14].

The new advancement in disease delaying programs includes kinase inhibitors, τ -aggregation inhibitors, and molecules targeting tau protein like modulators of τ -kinases or phosphatases. In addition to amyloid-plaque degradation enhancers and amyloid- β aggregation, inhibitors may also be incorporated in the management of AD [15]. The research progress is on to develop the diagnostic tools that can measure the neuro-biological indications of AD progression. Magnetic resonance imaging (MRI) and blood test (for Plasma A β) may improve the accuracy of diagnosis of AD symptoms. Genetic testing is generally not recommended for AD. However, in exceptional cases, family history of people with early-onset AD may be recommended [16 - 18].

Blood Brain Barrier and AD

Recently, only symptomatic treatments exist for all the disease, all treatment aims to counterbalance the neurotransmitter disturbance: cholinesterase inhibitors and memantine. For blocking the progression of the disease, therapeutic agents are supposed to interfere with the pathogenic steps responsible for the clinical symptoms, classically including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation. The blood-brain barrier (BBB) protects against circulating toxins and pathogens that could cause brain damage or

CHAPTER 5**Alzheimer's Disease and Physical Activity, Will the Symptoms Improve?****Maryam Hamzeloo-Moghadam^{1,*}**

¹ *Traditional Medicine and Materia Medica Research Center and Department of Traditional Pharmacy, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran*

Abstract: Alzheimer's disease is known to be the most common cause of dementia with increasing number of people suffering every year. In healthy adults, there are millions of neurons in the brain. Degeneration starts and extends in Alzheimer's disease many years before the initial symptoms show up. The neurons taking part in cognitive functions destroy gradually leading to functional disability and finally to death. β -amyloid plaques and tau protein are known as the most responsible causes of Alzheimer's disease resulting in neurodegeneration. Inflammation, atrophy and dysfunction in glucose metabolism will follow. The three stages of the disease include mild, moderate and severe. The patient will have difficulty in cognitive functions, show changes in behavior and will need care for everyday needs, which increases by the disease progress. There are pharmacologic and non-pharmacologic approaches for treatment. The pharmacologic approaches comprise acetylcholinesterase (AChE) inhibitors such as donepezil or N-methyl-d-aspartate (NMDA) receptor blockers like memantine. None of them stops the disease but alleviate the symptoms. On the other hand, non-pharmacologic approaches are usually used to improve the patient's quality of life or improve the behavioral aspects of the disease. Recently, involving physical activity as a non-pharmacologic method of treatment for Alzheimer's disease has been the focus of many studies. This chapter will have a glance at the clinical trials that were conducted regarding the effect of physical exercise and its impact on Alzheimer's disease.

Keywords: Alzheimer's Disease, Dementia, Exercise, Physical Activity.

INTRODUCTION

The first case of Alzheimer's disease was introduced by Dr. Alois Alzheimer in 1907; a 51-year old woman with unusual clinical observations. The first symptom

* **Corresponding author Maryam Hamzeloo-Moghadam:** Traditional Medicine and Materia Medica Research Center and Department of Traditional Pharmacy, School of Traditional medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; E-mail: mhmoghadam@sbm.ac.ir

was jealousy of her husband, which then progressed to memory loss, disorientation and hallucination. She died four and a half years later. Brain atrophy and arteriosclerotic change in vascular tissues and striking changes of the neurofibrils were reported by Dr. Alzheimer [1]. Histological analysis showed dense bundles of unusual fibrils in nerve cells and senile plaques in the cerebral cortex. The combination of the clinical and histological data came to be known as Alzheimer's disease (AD) [2].

Risk Factors

The most important risk factors for late-onset Alzheimer's disease are age, genetics and family history [3]. The role of older age and its association with Alzheimer's disease remarks the cumulative effects of factors like interactions of genetic susceptibility, biological factors, and environmental exposures [4]. Cardiovascular diseases, brain traumas, depression, diabetes mellitus, increase in LDL, elevation of plasma homocysteine, low skills in occupation or education, lack of intellectual, physical, social and leisure activities, stress and thus elevated plasma cortisone levels are other risk factors for Alzheimer's disease [5, 6].

Pathology

In Alzheimer's disease, synapses and neurons in the cerebral cortex are lost. The brain shrinks and neurofibrillary tangles (NFT), made up of hyperphosphorylated tau protein are formed inside neurons while amyloid deposits, known as plaques which consist of amino acid peptide (amyloid-beta or $A\beta$), are present outside neurons. The neurons die and the brain tissue is damaged. Alzheimer's disease slowly progresses. Many years before the symptoms show up, the disease has already begun [3, 4, 7].

Pharmacologic Treatment of Alzheimer's Disease

The currently used pharmacologic medications for Alzheimer's disease do not slow the progress or stop the destruction of neurons; they just alleviate the symptoms. There are two accepted categories of treatment that modulate the neurotransmitters in the brain, cholinesterase inhibitors and N- methyl- D- aspartate (NMDA) receptor antagonists [3, 8].

Cholinesterase Inhibitors

Cholinergic neurons are selectively reduced in Alzheimer's disease (AD). To overcome the situation, anti-cholinesterases, precursors of acetylcholine and cholinomimetics have been used for the treatment of AD with anticholinesterases being the most successful among them. Tacrine, donepezil, and galantamine reversibly inhibit acetylcholinesterase while rivastigmine is a reversible inhibitor of both acetylcholinesterase and butyrylcholinesterase. These enzyme inhibitors

prevent the breakdown of acetylcholine at the synapses of cholinergic neurons [4, 6, 8]. It should be noted that tacrine elevates the levels of serum aminotransferase and might induce liver toxicity [9].

N-methyl-D-aspartate (NMDA) Receptor Antagonists

Memantine belongs to this category and is able to block glutamate at its sites of action and protect neurons by improving synaptic transmission and/or preventing calcium release [6, 8].

Should Non-Pharmacologic Treatments Be Involved?

The most prevalent cause of dementia in older people is Alzheimer's disease making up 60-80% of all dementias. One in eight of adults over 65 are struggling with AD; yet, there are no solution for prevention or overcoming the disease [10].

Alzheimer's disease gradually results in cognitive deterioration, functional decrementation, dependency and reduced quality of life [11, 12]. Disabilities in patients with Alzheimer's disease force them to be dependent on their caregivers. Stiffness, weakness in muscles and more risk of falling are other points of concern [13]. Balance performance is disturbed in older people and thus they are more susceptible to fall, a situation worsened in dementia [14].

To support brain health in older people, both pharmacologic and non-pharmacologic treatments have been the focus of researchers (Fig. 1) . Clinical trials conducted in the recent two decades have tried to aim the pathological features, but other mechanisms also need to be considered [15, 16]. The available pharmacologic treatments just decelerate the symptoms, not stop them [17, 18] and may also cause unwanted effects such as gastrointestinal problems and insomnia. On the other hand, non-pharmacologic treatments can be used as alternatives or supplements [19].

Recently, there has been interest for research about non-pharmacologic treatments of Alzheimer's disease. Studies have shown that being involved in mental or physical activities will reduce the occurrence of dementia [18]. Some non-pharmacologic interventions for alleviating the behavioral symptoms of AD include educating the caregivers, managing the environment, psychotherapy, cognitive treatment, physical trainings, and occupational therapy [18, 20]. These interventions have positive effects on activities of daily living in AD patients [11, 21, 22].

SUBJECT INDEX

A

- Abuse 171, 175, 179, 182, 184, 186, 187, 202, 206, 208, 210
 initial immunotherapeutic methods
 combating Meth 206
 Acetylcholinesterase 6, 53, 251, 286, 287
 AchE 23, 39, 57, 59, 61, 65, 67, 69, 77, 81, 87, 115, 120, 124, 126, 128, 130, 131, 135, 243, 244, 251, 252
 acetylcholinesterase 243, 244
 activity 39, 128, 135, 252
 inhibition 23, 57, 59, 61, 65, 67, 69, 77, 81, 124, 126, 128, 130
 inhibitors 87, 120, 130, 131, 251
 inhibitory properties 61, 115
 AChE and BuChE 127, 252
 activity 252
 inhibitory properties 127
 Acid(s) 31, 32, 40, 41, 48, 78, 88, 95, 99, 100, 117, 123, 125, 136, 191, 241, 244, 247, 248, 249, 277
 ascorbic 117
 caffeic 48, 241, 248, 249
 chlogenic 248
 cinnamic hydroxyl 248
 coumaric 247
 gallic 88
 glutamic 40, 41
 Glycyhizic 277
 hydroxybenzoic 88
 hydroxycinnamic 244, 247
 kojic 125, 136
 lipoic 31, 32, 95, 136
 opionic 191
 phenolic 248
 Protocatechuic 88
 quinic 248
 salicylic 99, 100
 sinapic 248
 succinic 78
 TMP-phenolic 123
- Activation 7, 9, 20, 22, 43, 84, 87, 114, 115, 116, 171, 175, 176, 178, 195, 197, 251
 astrocyte 7
 glial 9
 neuron 171
 Activities 8, 22, 39, 44, 45, 46, 47, 55, 61, 68, 103, 106, 109, 111, 113, 118, 126, 243, 246, 250, 252, 255, 257, 269, 270, 277, 291
 anti-aggregating 45
 anti-amyloid aggregation 47
 anticholinesterase 270
 anti-cholinesterase 44
 antidepressant 126
 anti-fibrillogenic 45, 46
 anti-inflammatory 22, 55, 68, 103, 109, 118, 243, 277
 antimalarial 106
 anti-oxidant 246, 250, 252, 257, 269
 inhibited Acetylcholinesterase 270
 mTOR kinase 113
 oxidative stress scavenging 243
 radical scavenging 61, 111, 255
 reduced mitochondrial 8
 social gathering 291
 transcriptional 22
 urinary paraoxonase 39
 Addiction 163, 164, 165, 173, 179
 induced adaptations 173
 phenotypes 179
 syndrome 165
 theory 163, 164
 Addictive 163, 164, 165, 166, 182
 behaviors engagement 164, 166
 disorders 163, 164, 165
 phenotype 182
 Adenosine 9, 77
 receptors (ARs) 77
 triphosphate 9
 Adenylate cyclase 177
 ADMET properties 125
Aframomum melegueta 269

Zareen Amtul (Ed.)

All rights reserved-© 2023 Bentham Science Publishers

Subject Index

Age 5, 8, 10, 11, 180, 184, 242, 266, 287, 311
 chronological 184
Agent 254
 etiologic 254
Age-related brain demethylation 184
Aggregated proteins 245
Aggregates 9, 253
 non-fibrillar 253
Aggregation 7, 8, 32, 43, 44, 53, 57, 80, 84,
 86, 93, 101, 102, 103, 111, 120, 250
 inhibition 102
 reduced 250
 tau-induced 93
Aging 2, 3, 8, 10, 241, 242, 245, 256, 292
 sporadic 242
 actuated gathering 242
Alcohol 161, 189, 193, 194, 210
 drinking 189
 intake 189
 use disorder (AUD) 161, 189, 193, 194,
 210
Aldehyde dehydrogenase 8, 193
Alkylidene polyamine 125
Alzheimer's disease force 288
Ameliorate 20, 198, 270
 anti-oxidant phytochemicals 270
Amine 22, 27, 90, 120
 hybrids 90
 pharmacophore 22
Amino acids 271
AMPA receptors, glutamatergic 52, 54
Amygdala 168, 170, 174, 176, 178, 186, 189,
 191, 193, 195
 basolateral 170, 176, 186, 191, 193
Amyloid 6, 7, 44, 96, 244, 250, 274
 aggregation 244
 protein precursor (APP) 6, 7, 44, 96, 274
 transformation 250
Amyotrophic lateral sclerosis 10
Anabolic steroids 187, 200
Antagonists 77, 94, 97, 189, 202
 immune 202
Anthocyanides 277
Anthraquinones 92, 93
Antianxiety and brain tonic 270

FCDR - CNS and Neurological Disorders, Vol. 11 315

Antibodies 203, 204
 producing anti-nicotine 204
Anti-calmodulin action 270
Anticholinesterases 287
Anti-cholinesterases 68, 287
Anticocaine antibodies 204
Anti-compulsive effects 18
Anti-diabetic agents 269
Anti-inflammatory 20, 21, 35, 58, 80, 82, 83,
 105, 271
 agents 83
 effects 20, 21, 35, 58, 80, 82, 105
 nutraceuticals 271
Anti-methamphetamine 208
Anti-neuroinflammatory 83, 84, 100, 130, 136
 activities 83
 agents 84, 136
 effects 130
Anti-Nicotine vaccines 204
Antinociception, nicotine-induced 204
Antioxidant 12, 18, 34, 42, 43, 46, 58, 62, 63,
 65, 68, 83, 84, 85, 87, 88, 89, 90, 91,
 101, 103, 108, 109, 111, 115, 117, 119,
 122, 123, 125, 244, 251, 277
 concomitant 58
 effects, additional remarkable 88
 enzymes 43
 induced 251
 pathway 34
 profile 108
 properties 12, 18, 43, 46, 65, 68, 101, 103,
 109, 117, 123
 redox system 91
 response 115
 systemic 277
 toxic 111
Antioxidant activities 84, 86, 89, 91, 95, 96,
 108, 110, 111, 112, 113, 116, 117, 121,
 123, 134
 concomitant 134
Anxiolytic effects 183
Apoptosis 7, 8, 51, 53, 131, 245, 246
 anti-neuronal 131
 assays 53
 in neurological diseases 245

- inducing factors (AIFs) 246
- mitigating ROT-induced 51
- neuronal 7
- time-dependent neuron 8
- Arteriosclerosis 278
- Astrocytes 126, 245, 250, 271, 273
- Astrocytes via 250
- Astrocytogenesis 184
- Atherosclerosis 277
- Atrophy 286, 290
 - reduced hippocampal 290
- Autoimmune encephalomyelitis 20

B

- Balance, dynamic 298
- Behavioral 18, 161, 197
 - assays 18
 - neuroscience 161
 - therapies 197
- Behaviors 5, 170
 - drug-seeking 170
 - social 5
- Bioactive 69, 78
 - glycoside iridoid 69
 - metabolites 78
- Biosynthetic precursor choline
 - acetyltransferase 6
- Blood 248, 271, 289
 - cerebrospinal fluid 271
 - plasma 248
 - pressure, reducing 289
- Blood-brain barrier (BBB) 12, 33, 38, 265, 266, 267, 268, 269, 271, 272, 273, 274, 278
 - permeability 265
- Brain 7, 9, 10, 12, 161, 162, 163, 164, 168, 175, 180, 187, 190, 191, 209, 210, 244, 250, 266, 269, 271, 273, 287, 306
 - aging 269
 - anti-stress systems 190
 - cancer 269
 - defense system 7

- derived neurotrophic factor (BDNF) 12, 161, 180, 187, 210, 244, 250, 306
- disorders 269
- imaging technologies 162
- insulin resistance 269
- metabolism 9
- microglial cells 273
- motor neurons 10
- neuroadaptations 187
- neurochemical systems 191
- nutrients 271
- permeability 266
- reward circuits system 164
- reward system (BRS) 161, 163, 168, 175, 190, 209
 - stress systems 190, 191
 - traumas 287
- BuChE 15, 30, 63, 72, 81, 127, 128, 244
 - inhibition 30, 63, 72, 81, 127
 - inhibitors 15, 128, 244
- BuChE inhibitory properties 127, 133
- Butyrylcholinesterase 6, 36, 57, 251, 287

C

- cAMP 24, 60, 95, 120, 177
 - phosphorylates 177
- Cannabichromene 187
- Cardioprotective 277
- Cardiorespiratory 290, 305, 309, 310
 - condition 310
 - fitness 290, 305, 309
- Cardiovascular diseases 287
- Catecholaminergic systems 178
- Cell death 27, 47, 245, 246, 249, 251, 252, 253, 255
 - apoptotic 255
 - glutamate-induced neuronal 47
 - neuronal 245, 246, 249
 - regular non-apoptotic 245
- Cellular damage 24, 68, 75
 - oxidative 68
- Cerebellar granule neurons (CGNs) 75
- Chaperone systems 9

Subject Index

Chemical entities, neuroprotective 117
Chemicals 10, 184
 cigarette 184
Cholinergic 5, 132, 178, 272, 287, 288
 circuitry 178
 dysfunction 272
 hypothesis 132
 neurons 5, 287, 288
Cholinesterase 16, 22, 58, 72, 125, 128, 265,
 266, 267, 270, 287
 action 270
 inhibition 16, 58, 72, 125, 128
 inhibitors 22, 128, 265, 266, 267, 287
Cholinesterases 22, 72, 128
Chronic 253, 255
 neuroinflammation 253
 wasting disease (CWD) 255
Circuit, neuroplasticity 191
CNS-related 18, 101
 illnesses 18
 multi-target mechanism 101
Cocaine nitrogen 205
Coffe arrabica 248
Coffee 248, 249, 304
 black 248
Cognitive 161, 209, 288
 deterioration 288
 reactions 161, 209
Combination therapy 251, 304
Cortical 5, 17, 41, 79
 brain slices 79
 neurons 17, 41
 pyramidal neurons 5
Corticolimbic dopamine system 195
Corticotropin-releasing factor (CRF) 176, 178,
 190, 191, 192, 193
Coumarin 27, 29, 31, 33, 136, 271
 system 31
Craving 166, 190
 gratification 166
 stress-induced 190
CREB activation 186
Creutzfeldt-Jakob disease (CJD) 254
Curcuma 269, 270
 longa 269, 270

FCDR - CNS and Neurological Disorders, Vol. 11 317

zedoaria 269
Curcumin 34, 41, 42, 43, 44, 45, 46, 47, 50,
 51, 52, 53, 54, 136, 137, 270
 diazo-boron difluoride 44
 derivatives 52, 53, 54
 monoglucoside 52
 pyrazole derivatives 46
Curcuminoids 47
Cyclic guanosine monophosphate 24, 59
Cyclooxygenase, inhibiting 58
Cytotoxicity 21, 53, 67, 101, 102, 114, 273
 glutamate-induced 102
Cytotoxicity assays 88

D

Damage 5, 9, 17, 27, 36, 53, 58, 63, 79, 99,
 246, 254, 255, 256, 273
 glutamate-induced 79
 irreversible neuronal cell 255
 kainate-induced 99
 neuronal 5, 36, 53, 63
 neurons 9
 oxidative-induced 58
 oxidative stress brain 256
Death, neuronal 8, 96, 114, 251, 269
Deficits 6, 53, 60, 88, 164, 242, 245
 ameliorate learning 60
 cholinergic 6, 53
Degeneration 6, 10, 286
 neuronal 6
Dementia 1, 2, 3, 5, 11, 286, 288, 289, 290,
 297, 305
Dendritic spine density 255
Deposition 8, 12, 53, 119, 251, 267
 extracellular Tau neurofibrils 53
 fibril 119
Deposits 6, 287
 amyloid 287
Depression 8, 167, 241, 269, 287, 290, 299,
 300, 309
 reducing 300
Diabetes mellitus 287, 293, 304

- Disease(s) 4, 6, 15, 89, 94, 199, 241, 242, 243, 245, 250, 251, 252, 254, 265, 267, 276, 277, 278, 286, 287, 288
 modifying agents 15
 progression 6, 199, 250, 265, 267
 age-related 89
 chronic multifactorial 4
 cognitive 252
 neuronal 94
 peripheral vascular 276
 progressive neurological 251
- Disorders 1, 89, 163, 167, 185, 189, 197, 241, 254, 266, 269, 278, 293, 308
 ameliorate sleep 89
 chronic relapsing 189, 197
 metabolic 241
 neurodegenerative 241, 254, 266, 269, 278
 neuropsychiatric 293, 308
 psychiatric 185
- DNA 21, 110, 125, 181, 182, 183, 245, 246
 alkylating agents 246
 cytosine methylation 183
 damage 245
 methyltransferases 182, 183
 protection 125
 protective effect 110
 repair 181
- DNA epigenetic 184, 185, 186
 dynamics 185
 machinery 184, 186
- DNA methylation 182, 184, 185
 age-related 184
- Donepezil 59, 67
 based multifunctional agents 59
 coumarin hybrids 67
- Dopaminergic neurons 5, 8, 9, 250
 damaged 9
- Dopaminergic nigrostriatal system 249
- Drug delivery systems 265, 266, 271, 273, 278
 conventional 273
- Drug(s) 161, 164, 170, 172, 177, 183, 186, 187, 199, 201, 203, 210, 268, 296
 abusing 170
 addiction 161, 164, 170, 183, 187, 199, 201, 210
 addictive 164, 172, 177, 186, 210
 anti-diabetic 268
 immunoconjugate 203
 psychotropic 296
 triggered relapse 177
- Dynamic light scattering (DLS) 74
- Dysfunction 8, 11, 12, 165, 190, 242, 249, 251, 265, 268, 270, 271, 286, 295
 behavioral 265, 271
 cognitive 251, 295
 neuronal 11
 synaptic 12, 242, 270
- Dysregulation 6, 163, 164, 191, 242, 251, 256
 brain reward systems 163
 intracellular calcium 242, 256
 theory 163
- ## E
- Eicosanoids 253
- Emotional Buffer Systems 191
- Endocannabinoids 15, 18, 169, 189, 191, 192, 209
 system 15, 18
- Endogenous opioid system 178
- Enzyme(s) 12, 63, 195
 catalyze 63
 monoaminoxidase 12
 systems 195
- Erythropoietin 22
- Essential oils (EOs) 178, 269
- Excitotoxicity 8, 11, 17, 52, 54, 55, 126, 128, 242, 246, 256
 glutamate-induced 126
- Exercises 290, 292, 296
 balancing 292
 community-based 292
 multitasking 296
 toning 290
- Extracellular signal-related kinase 173

F

FAAH inhibitors 189
 Factors 8, 22, 161, 176, 179, 187, 190, 192,
 193, 210, 241, 242, 246, 250, 254, 256,
 266, 287, 289, 306
 apoptosis-inducing 246
 brain-derived neurotrophic 250, 306
 corticotropin-releasing 176, 190, 192, 193
 genetic 161, 179, 210
 hypoxia-inducible 22
 inflammatory 289
 relapse triggering 187
 sporadic 241, 242, 254, 256
 trophic 242
 Fast-spiking GABAergic interneurons 170
 Fatty acid amide hydrolase (FAAH) 171
 FDA-approved medications 189
 Fentanyl conjugate vaccine 209
 Ferulic 48, 243, 247, 249
 synthesize 249
 Ferulic acid 43, 50, 51, 56, 58, 80, 81, 95,
 123, 124, 241, 244, 246, 248, 249
 donepezil hybrids 80, 81
 scaffold 43
 Flavin adenine dinucleotide (FAD) 91
 Fragments 86, 79, 90
 aminochalconevin 86
 aminoguanidine 79
 pharmacophoric 90
 Free radicals assay 48
 Freund's adjuvants 207
 Function 7, 17, 46, 176, 181, 184, 185, 190,
 204, 242, 251, 254, 269, 272, 303, 306
 abnormal brain 269
 abnormal cellular 242
 gonadal hormones 185
 mitochondrial 46, 251, 254
 neuronal 272
 scavenging 7
 Furocoumarin 118

G

GABAergic 169, 171, 178, 179
 interneurons 171
 neurons 169, 171
 pathways 178
 systems genes 179
 GABA 171, 190
 release pathway inhibition 171
 transmission 190
 Gastrointestinal 249, 288
 problems 288
 tract 249
 Gene(s) 20, 21, 22, 84, 179, 180, 181, 182,
 183, 184, 185, 187, 195, 242
 anti-inflammatory 84
 dopaminergic system 179
 genetic 242
 ontology 195
 opioid systems 179
 Genotoxicity 110
 Glial fibrillary acidic protein (GFAP) 244,
 250
 Globus pallidum (GP) 174
 Glucocorticoids 191
 Glucopyranosyl lipid Adjuvant (GLA) 206
 Glucose metabolism 21, 268, 286, 304, 305
 ameliorated 305
 Glutamate 10, 11, 52, 54, 55, 79, 176, 178,
 191, 192, 193, 195
 neurotransmitter 176, 178
 Glutamate release 17, 79, 171
 inhibiting presynaptic 171
 Glutamatergic 170, 171, 173, 188, 190, 191
 projection 188, 191
 systems 190
 transmission 173
 Glutamate system 193
 Glutamine amino acids 253
 Glutathione 20, 69, 84, 250, 253
 defense system 84
 peroxidase 69
 reduced 253
 Gonadotropin-releasing hormone 173
 GPCR-induced intracellular signaling 173

GSH levels 39, 102
Gut 255, 256, 275
 bacteria 275
 microbiota 255, 256
GWAS analyses 179, 181

H

Haemorrhoids 278
Hallucination 287
Hallucinogens 162, 187, 200
Headache 193, 194
Hedonic processing systems 175
Hemeoxygenase 20
Hepatocarcinoma 88
Hepatoprotective 69
Hepatotoxicity 67, 75, 105, 120, 121, 124
 assay 121
Herbal preparations 269
Heroin 207
 antinociception 207
 vaccine 207
HerSH conjugate vaccine 207
Heterogeneous brain cell populations 183
High-throughput screening (HTS) 198
Hippocampal 5, 19
 and cortical pyramidal neurons 5
 neurons 19
Hippocampus 5, 6, 59, 91, 174, 176, 178, 183,
 184, 193, 195
Histamine receptors (HRs) 93, 94, 98
Histone 134, 182, 255
 acetyltransferases 182
 deacetylases 134, 182, 255
 demethylases 182
 methyltransferases 182
Homeostasis 7, 8, 20, 21, 268, 273, 277
 reductase 20
HPA stress response 178
Human 21, 50, 114, 125
 duodenum preparation 114
 hepatocytes 125
 neuroblastoma SH-SY5Y cells assay 50
 oligodendrocyte cells 21

Huntington 241, 253
 disease 241
 gene 253
Huntington's disease (HD) 2, 5, 11, 12, 79,
 84, 241, 242, 243, 244, 245, 253, 254
Hybrid(s) 31, 39, 62, 69, 72, 101, 111, 116,
 119, 133
 derivatives 39, 62, 72, 101, 111, 116, 119,
 133
 lipoic acid-coumarin 31
 organoselenium 69
Hydrolysis 47, 78, 95
Hydrolyzing phospholipase 171
Hyperglycemia 268
Hypoglycemia 255
Hypothalamus 176, 178
Hypothermia 204
Hypoxia-inducible factor (HIF) 22

I

Inflammation 10, 21, 24, 58, 114, 250, 253,
 267, 286, 306
Inflammatory-related chronic illnesses 21
Inhibition, enzymatic 93
Inhibitors, acetaldehyde dehydrogenase 193
Inhibitory 75, 81, 82, 93, 94, 97, 102, 103,
 118, 119, 120, 130, 132, 133
 activity 75, 81, 82, 94, 97, 102, 103, 118,
 120, 130, 132
 profile 119
 properties 93, 133
Insomnia 267, 288
Insulin 268, 269, 305
 deficiency 268, 269
 sensitivity 305
Interactions 36, 179
 gene-environment 179
 modulating protein-protein 36
Iron deregulation 267
Ischemia 79, 246, 255
 cerebral 79, 255
Ischemic brain injury 255

Subject Index

K

Key neurotransmitter systems 193
Kleptomania 163
Knowledgebase for addiction-related genes
(KARG) 173

L

Lactate dehydrogenase 53, 79, 113
Lateral sclerosis 2, 10
Leukotrienes 253
Ligustrazine 122
Lipid-rich biological membranes 275
Lipoperoxidation 8
Lipophilicity 109
Lipopolysaccharide 34
Liposomes 265, 266, 273, 274
Liver 276, 288
 function 276
 toxicity 288
Lymphokines 253
Lysosomal 8, 9
 autophagy system 9
 systems 8
Lysosome 245, 253
 acidification 245
 biogenesis 253

M

Macrophages 114
Magnetic resonance imaging (MRI) 267
Malfunctioning 185
Mammalian glycoprotein 274
MAO 12, 25, 63, 67, 93, 107, 109, 110
 inhibition 25, 63, 67, 93
 inhibitors 12, 107, 109, 110
MAPK autophosphorylation 171
Mechanisms 41, 163, 168, 169, 180, 209, 269,
 296
 allostatic 163
 cellular 269

FCDR - CNS and Neurological Disorders, Vol. 11 321

 genetic 180
 glutamatergic 169, 209
 inhibitory 168
 metabolic 296
 mTOR-dependent 41
 neuro-adaptive 163
Medial forebrain bundle (MFB) 168, 175
Medication(s) 189, 197, 210, 242, 251, 287,
 296, 298
 assisted treatment (MAT) 197, 210
 pharmacologic 287
Medicinal plants 246, 265, 269, 270
 traditional 269
Medicine(s) 27, 266
 herbal 266
 preparations, traditional 27
Melatonin 37, 89, 90, 91, 92
 hybrids 89
Memory 3, 5, 25, 53, 60, 64, 173, 241, 255,
 266, 287, 290, 294, 296, 302, 304, 305,
 306, 307
 cognitive 25
 function 173
 games 294
 impairments 255
 loss 241, 266, 287, 305
Memory performance 23, 60, 290, 302, 305
 spatial 60
 visual 302
Memory enhancer action 270
 theophylline 270
Mental disorders 162
Mesocorticolimbic dopamine system 190
Mesolimbic 175, 182
 dopamine system 175
 system 182
Metabolism 6, 7, 114, 179, 198, 205, 242,
 243, 246, 267
 cellular 6
 cholesterol 267
 mitochondrial dynamics 243
Metabolites 69, 78, 114, 207
 natural 69
Metal-protein attenuation compounds
 (MPACs) 23

- METH-conjugate vaccine (MCV) 206, 207, 208
- Michael addition 115
- Microglial cells 20, 271
- Mild cognitive impairment (MCI) 305, 306
- Mimic(s) 68, 134
 - glutathione peroxidase 134
 - organoselenium glutathione peroxidase 68
- Mirtoselect phytosomes 277
- Misfolded proteins 9, 245, 256
- Misfolding 63, 273
 - amyloid peptide 273
 - process 63
- Mitochondria 7, 9, 11, 37, 46, 242, 245, 246, 254
 - damaged 9, 245
 - function 46
- Mitochondrial 7, 122, 254
 - biogenesis 254
 - biosynthesis 122
 - permeability transition pores (MPTP) 7
- Mitochondrial dysfunction 3, 6, 8, 9, 10, 42, 242, 243, 244, 249, 251, 254
 - modulator 244
- Mitogen-activated protein kinase (MAPK) 171, 172, 173, 252
- Molecular hybridization 50, 51
 - of ferulic acid 51
 - of tacrine 50
- Molecular hybrids 5, 12, 25, 64, 95
- Monoclonal antibodies 161, 208, 209, 244
- Montgomery 300
- Morris water-maze test 60
- MPLA-containing liposomes 207
- MPTP-induced neurotoxicity 250
- MTT 21, 50, 93
 - assay 21, 50, 93
 - test in human oligodendrocyte cells 21
- Multiple sclerosis (MS) 20, 21, 241, 243
- Multi-target 17, 30, 104, 107, 118, 121, 132
 - hybrids 121
 - mechanism 17, 118
 - pharmacological profile 107
 - properties 30, 104, 132
- N**
- Nervous system 5, 11, 190, 241
 - dysfunction 241
 - hyperactivity 190
- Neuroadaptations 191
- Neuroanatomy 170
- Neurobiological 164, 199
 - disorders 199
 - factors 164
- Neurobiological 163, 168
 - pathways 168
 - theories of behavioral addiction 163
- Neurobiology 3, 166, 174
 - pathways 174
- Neuroblastoma 36, 88, 125, 130
 - human 88, 125
 - cells 130
- Neurocircuitry neuroadaptations 174
- Neurodegeneration, pathological 306
- Neurodegenerative pathology 244
- Neurofibrillary tangles 251, 287
- Neurofibrils 287
- Neurogenesis 41, 91, 184, 289
 - modulate hippocampal 91
 - promoted 41
- Neuroinflammation 3, 7, 8, 9, 12, 21, 24, 58, 83, 92, 250
- Neuroinflammatory 6, 58
 - process 58
- Neurological 242, 243, 244, 245, 256, 257
 - diseases 242, 243, 244, 245, 256, 257
 - problems 242
- Neurological risk factors of behavioral addiction 162
- Neuromodulator systems 191
- Neuronal 2, 3, 8, 11, 27, 32, 51, 58, 85, 113, 130, 251, 273
 - cells 2, 3, 27, 32, 51, 58, 85, 113, 130, 251, 273
 - vulnerability 8, 11
- Neurons 3, 5, 8, 9, 100, 101, 168, 170, 171, 176, 184, 250, 251, 286, 287, 288
 - cerebellar 184

Subject Index

Neuropathologies 83, 96
Neuropeptide 190, 191, 192
Neuroplasticity 192, 289
Neuroprotection 19, 20, 24, 27, 58, 61, 99, 100, 101, 130, 131, 243, 244
Neuroprotection effect 41
Neuroprotective 14, 15, 17, 26, 37, 41, 42, 49, 51, 52, 54, 55, 73, 82, 98, 103, 110, 112, 113, 114, 115, 241, 243, 256, 271
agents 17, 26, 37, 49, 73, 82, 98, 103, 241
effects 14, 15, 41, 42, 51, 52, 54, 55, 110, 112, 113, 114, 115, 256, 271
therapeutics 241, 243
Neuropsychiatric 294, 298, 299, 307, 309, 310
disturbances 294
problems 310
symptoms 298, 299, 307, 309, 310
Neuropsychopharmacology 174
Neurotoxic aggregates 8
Neurotoxicity 8, 9, 10, 14, 21, 25, 48, 54, 75
glutamate-induced 48
Neurotoxins 8, 9
Neurotransmitter(s) 6, 9, 63, 177, 178, 191, 192, 193, 195, 196, 251, 287, 289
norepinephrine 178
release 195
Neurotransmitter systems 192, 193, 205, 209
regulating monoamine 205
Nicotine 161, 170, 172, 179, 184, 195, 196, 197, 203, 204, 208, 209, 210
addiction 195, 196
binding 195
delivery systems 196, 210
enantiomer 204
exposure 184, 195
inhalation cartridge 196
metabolite ratio (NMR) 197
pharmacodynamics 197
replacement therapy (NRT) 195, 196, 197, 210
Nicotine vaccine 203, 204
synthetic 204
Nitroguanidine 246
NMDA-antagonists 128
NMDA receptor 18, 189

FCDR - CNS and Neurological Disorders, Vol. 11 323

antagonists 18
function booster 189
NMDAR antagonist ketamine 189
Nutritional supplementation 304

O

Oligodendrocytogenesis 184
Oligodeoxynucleotides 203
Olive 249, 277
oil phytosomes 277
processing industries 249
Opioids use disorder (OUD) 161, 181, 189, 197, 198, 210
Orthogonal assays 198
OS-related diseases 89
Oxidative stress 3, 6, 19, 58, 119, 242, 249, 251, 255, 256, 269
induced 19
pressure 242
reactive 242
Oxygen 12, 41
Oxytocin 191, 192

P

Pain 94, 162
neuropathic 94
Pair helical filaments 6
PAMPA assay 38, 62, 67, 70, 75, 84, 102, 110
Pancreatitis 165
Parkinsonism 8
Parkinson's disease (PD) 2, 3, 5, 7, 8, 9, 10, 12, 13, 77, 78, 242, 249, 250, 251
Pathogenesis 10, 12, 24, 90, 93, 129, 181, 268
complex multifactorial-based 12
of Alzheimer's disease 268
Pathways 19, 34, 96, 168, 172, 177, 178, 185, 196, 201, 247, 250
amyloidogenic 96
anti-apoptosis 34
anti-apoptotic 19
autonomic nervous system innervation 201
cholesterol-biosynthetic 250

- glutamatergic 177
- mevalonate-shikimate biosynthesis 247
- neural 168
- neural signaling 185
- neuroactive ligand-receptor interaction 172
- neurodevelopment-related signal 196
- neuroplasticity 201
- neurotransmission 201
- stress brain 178
- Peptide 6, 204, 206, 287
 - amino acid 287
 - synthetic 206
- Perkin reaction 249
- Permeability 12, 19, 92, 267, 277
 - blood-brain 267
 - blood vessel 277
- Peroxisome-proliferator 19
- Perturbation, energy supply 3
- PFC projections 183
- Pfizer nicotine vaccine 204
- Pharmacodynamic properties 198
- Pharmacokinetic restrictions 42
- Pharmacologic treatment 287, 289
 - of Alzheimer's disease 287
- Phytosomes technology 266, 275
- Piperazine isosteres 72
- Plaques 6, 61, 251, 267, 287
 - neuritic 6
 - senile 61, 251, 287
- Plasma 172, 287
 - homocysteine 287
 - membranes transduce 172
- Plasticity 60, 306, 307
 - natural 306
- Polyglutamine 253, 254
 - diseases 254
- Polygonum cuspidatum 269
- Polymers 246, 253, 272, 273
 - biocompatible 272
 - biodegradable 273
- Postsynaptic 17
 - effects 17
 - GABAA-receptor 17
- Post-translational modifications (PTMs) 181
- Prefrontal cortex 185
 - postmortem 185
- Prefrontal cortex 176, 188
 - neurons 188
 - system 176
- Prevalence, ethnical-dependent 11
- Prion 241, 243, 244, 254
 - disease 241, 243, 244, 254
 - protein 254
- Probabilistic matrix factorization (PMF) 200
- Processes 3, 7, 8, 9, 11, 36, 166, 168, 179, 181, 190, 245, 277
 - biochemical 277
 - degenerative 8
 - migration 11
 - neurodegenerative 9
 - oxidative 3
 - protein aggregation 7
 - regulating DNA-related 181
- Procyanides 277
- Production 6, 7, 8, 11, 20, 23, 34, 63, 114, 117, 244, 246, 250, 251
 - concomitant 63
 - cytokine 20
 - energy 11
 - neurotoxic 23
- Pro-inflammatory cytokines 7, 35, 251, 253, 255
 - releasing 255
- Pro-inflammatory 9, 22, 253
 - effects 22
 - mediators 9, 253
- Properties 13, 15, 19, 21, 22, 39, 40, 46, 47, 48, 65, 66, 79, 83, 85, 102, 103, 110, 122, 130, 204, 208, 265, 270, 271, 272, 273, 275, 276
 - anti-apoptosis 39, 40
 - anti-cholinesterase 102
 - anti-inflammatory 21, 22, 66, 83, 103, 130, 273
 - anti-ischemic 79
 - cholinergic binding 265, 270
 - gastroprotective 275
 - hepatoprotective 276
 - hepato-protective 122
 - immunological 273

Subject Index

metal chelating 47, 65, 85
Protease-sensitivity 255
Protection 40, 48, 99, 245, 272, 277
 neuronal 99
Protein(s) 8, 10, 11, 77, 84, 96, 126, 171, 177,
 179, 182, 198, 199, 201, 243, 244, 250,
 253, 254, 255, 268, 274, 304
 acidic 250
 aggregation 77
 amyloid precursor 96, 274
 anti-apoptotic 255
 calcium-binding 126, 253
 cyclic AMP-responsive element binding 182
 damaged 84
 genes encoding 179
 huntingtin 11
 infectious misfolded amyloidogenic 254
 neuronal cell transporter 10
 processing 8
 protein interactions networks 199
 regulatory element binding 177
Protein deposition 3, 7, 306
 reduced disordered 306
Protein kinase 129, 171, 172, 173, 250, 252,
253
 mitogen-activated 171, 172, 173, 252
 protein-dependent 250
 proto-oncogene 253
Psychological distress 165
Psychosis 298
Psychotherapy 288
Putative psychoactive effects 179

Q

Quantitative systems pharmacology (QSP)
 161, 199

R

Radical 42, 127
 scavenger 42
 scavenging agents 127
Radical scavenging 34, 117

FCDR - CNS and Neurological Disorders, Vol. 11 325

assays 117
 properties 34
Raynaud's disease 276
Reaction, click cycloaddition 32
Reactive 6, 7, 31, 63, 73, 75, 242, 245, 246,
 251, 253, 254
 gliosis 254
 nitrogen species 6, 253
 oxidative stress (ROS) 6, 7, 31, 63, 73, 75,
 242, 246, 253
 oxygen species 6, 245, 246, 251
Redox defense system 20
Reduced lipid peroxidation 40
Regulation 101, 173, 251, 305
 impaired glucose 305
Rehabilitation program 304
 psychomotor 304
Relapse 164, 165, 177, 178, 187, 188, 190,
 191, 194, 197, 210
 preventing 194
 reducing 194
Respiration 7, 301
 imbalanced cellular 7
Responses 4, 9, 34, 173
 microglia-mediated inflammatory 9, 34
 postsynaptic nerve cell 173
 therapeutic 4
Risk 21, 181, 185, 288, 294, 296, 297, 304,
 305, 306, 307, 309, 310
 environmental 181
 sexually-dimorphic 185
RNA 181, 182, 209
 polymerase II 182
 transcription 181
 translation 209
Role 126, 128, 187
 homeostatic 187
 neurotrophic 126
 pathological 128
ROS inhibitory activities 79
ROS production 25, 91, 102, 107, 112, 130
 preventing 102
 reducing cellular 112
ROT-induced damage 52

S

Saponin-phospholipid complexes 278
SAR analysis 65, 120
Savia officinalis 270
Scavenging activity 34, 256
 anti-oxidants 256
Schizophrenia 94, 269
Screening 105, 198
 phenotypic 198
Sensitisation-related neuro-adaptations 164
Sensory neurons 19
Serotonin 189, 192, 193, 195
Sex-dependent DNA methylation alterations 184
Signaling 7, 43, 60, 170, 171, 173, 178, 185, 269
 brain insulin 269
 pathway 43, 60, 173, 185
Signal(s) 7, 10, 24, 168, 173
 electrical 173
 extracellular 24, 173
 neuronal 168
 transmissions 10
Signal transduction 201, 202
 pathways 201
Silybum marianum 276
Smoke, inhalation 195
Smoking 165, 180, 187, 195, 196, 197, 305
 cessation therapy 195
 cigarette 180, 187, 196
Solid lipid nanoparticles (SLN) 273, 274
Spongiform encephalopathy 255
Stressors elicit CRF synthesis 178
Stress systems 175, 178, 191
 extrahypothalamic brain 178, 191
Stress-triggered relapse 178
Striatum, ventral 176
Structure-activity relationship (SAR) 48, 115, 198, 252
Substance 162, 268, 269, 271
 ingesting psychoactive 162
 lipophilic 271
 neurotoxic 268

 phytochemical 269
Substantia nigra 5, 8, 9
Succinate dehydrogenase 254
Succinylnorcocaine 204, 205
Sulfonamide 38
Sulfonylhydrazone 65
Superoxide dismutase 43, 271
Synaptic plasticity 173, 178, 184, 185, 186, 187
 drug-induced 187
Synaptic transmission 60, 184, 256
Synaptogenesis 306
Synthase 34, 246
 neuronal nitric oxide 246
Synthesis 13, 23, 32, 46, 55, 66, 79, 121, 247, 249
 propenoic acid fragment 249
Synthetic 51, 203
 chemistry technique 203
 curcumin monoglycosides 51
Synucleinopathies 249

T

Tachycardia 193
Tacrine-loaded chitosan nanoparticle 272
Tau 12, 53, 63, 83, 84, 93, 129
 aggregation 53, 93
 hyperphosphorylation 83
 neurotoxicity 53
Tau oligomers 6, 53
 recombinant 53
Tauopathies 53
Tau protein 6, 38, 53, 76, 267, 286, 287
 aggregation 76
 cascades 38
 hyperphosphorylated 287
 oligomeric 53
 targeting 267
Tau protein 53, 130
 oligomers 53
 phosphorylation 130
Tea, green 274, 277
Terpene lactones 276

Subject Index

Terpenoids 275
Testosterone 185
Tetrodotoxin 79
Thea sinensis 277
Theoretical models of addictive disorders 164
Therapeutic(s) 60, 70, 98, 100, 137, 195, 243, 250, 252, 255, 276
 applications of phytosome 276
 development 252
 smoking cessation 195
Therapy 267, 270, 274, 288, 301
 cognitive 301
 conventional 267, 274
 herbal 270
 occupational 288
Tight junctions (TJs) 271
Time-dependent DNA modifications 183
Tissue 9, 11, 245
 injured 9
 neuronal 11
TMOG assay 20
Tobacco 162, 187, 195, 197
 nicotine cause 195
 use disorder (TUD) 195, 197
Total radical-trapping antioxidant parameter (TRAP) 277
Toxic effects 4, 19, 101, 105, 110, 117, 122
Toxicity, oxidative 75
Toxins 10
Trampoline jumping 292
Transcription factors 182, 198
Transcytosis 271
Translocation events 202
Transport 11, 269
 reduced insulin 269
Transportation 301
Transporters 11, 195, 205, 249, 268
 monocarboxylic acid 249
 reduced astroglial glutamate 11
Treatment 2, 288, 289
 medical 2
 non-pharmacologic 288, 289
Tumor necrosis factor-alpha 9
Tyrosine 87, 250
 hydroxylase 250

FCDR - CNS and Neurological Disorders, Vol. 11 327

kinases 87

U

Ubiquitin-proteasome system 254

V

Vaccine 202, 203, 204, 205, 206, 208, 209
 anticocaine 205
 first-generation 206
 functional 204
 mAb-active 209
Vascular health 289
Vascularization, changing 307
Vascular tissues 287
Ventral Pallidum (VP) 168, 170, 176, 177
Virus-like particle (VLP) 204
Voltage-gated calcium channel (VGCC) 101
Vomiting 193, 267

W

Western blot analysis 113, 255
World Health Organization (WHO) 197, 210

Z

Zingiber officinale 270
Zizophus spinosa 270

ZAREEN AMTUL

Dr. Amtul, due to her background in clinical psychiatry and neurodegenerative disorders, brings expertise in neuroanatomy, pathophysiology, drug development, and diagnosis of brain disorders. Dr. Amtul's main area of research has been chemical biology and medicinal bioinorganic chemistry. Dr. Amtul has extensively researched the biochemical, molecular, and behavioral substrates of memory impairment in Alzheimer's disease, vascular cognitive impairment, stroke, depression, epilepsy, and frontotemporal dementia-related disorders using biochemistry, structural biology, optogenetics, decoy, and Trojan horse technologies, bioinformatics, and computational biology. Dr. Amtul is a recipient of several national and international awards in basic and SoTL research, including J. William Fulbright Award from the USA, the Alexander von Humboldt-Stiftung Award from Germany, Ontario Mental Health Foundation, and the CIHR Strategic Training Awards from Canada, as well as a few International Traveling grants.